Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

June 27, 2024

https://www.globenewswire.com/news-release/2024/06/27/2905204/0/en/Gain-Therapeutics-Presents-GT-02287-Data-at-Federation-of-European-Neuroscience-Societies-FENS-Forum-2024-Demonstrating-Improvements-in-Cognitive-Performance-in-a-Preclinical-Model.html

BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq:GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the presentation of a poster at the Federation of European Neuroscience Societies (FENS) Forum 2024. The poster describes improvement in cognitive performance and activities of daily living associated with administration of GT-02287 the Company’s lead novel allosteric therapeutic candidate in a mouse model of GBA1-Parkinson’s disease (GBA1-PD). FENS Forum 2024 is being held June 25–29, 2024 in Vienna, Austria.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.